E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD) |
|
E.1.1.1 | Medical condition in easily understood language |
Central Nervous System disorder causing primarily swelling and inflammation of the eye nerves and the spinal cord |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029322 |
E.1.2 | Term | Neuromyelitis optica |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy and safety of SA237 compared with placebo in patients with NMO and NMOSD |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients must meet the following criteria for study entry:
1. Patients must be diagnosed as having either:
a. NMO as defined by 2006 criteria*, or
b. NMOSD as defined by either of the following Wingerchuk 2007 criteria with anti-aquaporin 4 antibody (AQP4Ab) seropositive status at screening‡.
i) Idiopathic single or recurrent events of longitudinally extensive myelitis (≥3 vertebral segment spinal cord magnetic resonance imaging [MRI] lesion)
ii) Optic neuritis: recurrent or simultaneous bilateral
For patients aged 12 to 17 years, a minimum of 6 patients should be positive for anti-AQP4Ab status at screening‡.
‡ Screening result is based on either the blood sample data collected at screening visit, or the blood sample data collected before the screening visit and measured by Sponsor’s designee for analysis.
2. Clinical evidence of at least 2 documented relapses (including first attack) in the last 2 years prior to screening, at least one of which has occurred in the 12 months prior to screening.
3. Expanded Disability Status Scale (EDSS) score from 0 to 6.5 inclusive at screening.
4. Age 12 to 74 years, inclusive at the time of informed consent.
5. One of the following baseline treatments for relapse prevention must be at stable dose as a monotherapy for 8 weeks prior to baseline**:
a. Azathioprine.
b. Mycophenolate mofetil.
c. Oral corticosteroids.
** For patients aged 12 to 17 years, either of the following baseline treatments for relapse prevention can be allowed:
d. Azathioprine + oral corticosteroids.
e. Mycophenolate mofetil + oral corticosteroids.
6. Ability and willingness to provide written informed consent and to comply with the requirements of the protocol.
*According to Wingerchuk et al. 2006, a diagnosis of NMO requires all of the following three criteria:
I. Optic neuritis
II. Acute myelitis
III. At least two of three supportive criteria:
- Contiguous spinal cord lesion identified on an MRI scan extending over 3 vertebral segments
- Brain MRI not meeting diagnostic criteria for multiple sclerosis
- NMO-immunoglobulin G seropositive status |
|
E.4 | Principal exclusion criteria |
Exclusion criteria related to previous or concomitant therapy:
1. Any previous treatment with interleukin-6 (IL-6) inhibitory therapy (e.g. tocilizumab), alemtuzumab, total body irradiation or bone marrow transplantation at any time.
2. Any previous treatment with anti-cluster of differentiation (CD) 20, eculizumab, belimumab, interferon, natalizumab, glatiramer acetate, fingolimod, teriflunomide or dimethyl fumarate within 6 months prior to baseline.
3. Any previous treatment with anti-CD4, cladribine or mitoxantrone within 2 years prior to baseline.
4. Treatment with any investigational agent within 3 months prior to baseline.
Exclusions for general safety:
5. Pregnancy or lactation.
6. For patients of reproductive potential, a positive result from a serum pregnancy test at screening, or not willing to use reliable means of contraception (physical barrier [patient or partner], in conjunction with a spermicidal product, contraceptive pill, patch, injectables, intrauterine device or intrauterine system) during the treatment period and for at least 3 months after the last dose of study drug.
7. Any surgical procedure (except for minor surgeries) within 4 weeks prior to baseline.
8. Evidence of other demyelinating disease or progressive multifocal leukoencephalopathy (PML).
9. Evidence of serious uncontrolled concomitant diseases that may preclude patient participation, such as: other nervous system disease, cardiovascular disease, hematologic/hematopoiesis disease, respiratory disease, muscular disease, endocrine disease, renal/urologic disease, digestive system disease, congenital or acquired severe immunodeficiency.
10. Known active infection (excluding fungal infections of nail beds or caries dentium) within 4 weeks prior to baseline.
11. Evidence of chronic active hepatitis B or C.
12. History of drug or alcohol abuse within 1 year prior to baseline.
13. History of diverticulitis that, in the Investigator’s opinion, may lead to increased risk of complications such as lower gastrointestinal perforation.
14. Evidence of active tuberculosis (TB; excluding patients receiving chemoprophylaxis for latent TB infection).
15. Evidence of active interstitial lung disease.
16. Receipt of any live or live attenuated vaccine within 6 weeks prior to baseline.
17. History of malignancy within the last 5 years, including solid tumors, hematologic malignancies and in situ carcinoma (except basal cell and squamous cell carcinomas of the skin, or in situ carcinoma of the cervix uteri that have been completely excised and cured).
18. History of severe allergic reaction to a biologic agent (e.g. shock, anaphylactic reactions).
19. Active suicidal ideation within 6 months prior to screening, or history of suicide attempt within 3 years prior to screening.
Laboratory exclusion criteria (at screening):
20. Following laboratory abnormalities at screening*.
a. White blood cells <3.0 x103 /μL
b. Absolute neutrophil count <2.0 x 103/μL
c. Absolute lymphocyte count <0.5 x 103 /μL
d. Platelet count <10 x 104/μL
e. Aspartate aminotransferase or alanine aminotransferase >1.5 times the upper limit of normal.
* If retest is conducted, the last value of retest before randomization must meet study criteria.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time to first protocol-defined relapse (TFR) in the double-blind period.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Time to first protocol-defined relapse (TFR) in the double-blind period. |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints:
i. Change in visual analogue scale (VAS) for pain
ii. Change in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue
iii. Change in Short Form generic health survey score (SF-36)
iv. Change in EQ-5D
v. The proportion of relapse-free patients
vi. Annualized relapse rate (ARR)
vii. Change in modified Rankin Scale (mRS)
viii. Change in Zarit Burden Interview (ZBI)
ix. Change in Expanded Disability Status Scale (EDSS)
x. Change in visual acuity (Snellen chart)
Pharmacodynamic endpoints:
IL-6, soluble IL-6 receptor, high sensitivity C-reactive protein, anti-AQP4 antibodies and plasmablasts.
Pharmacokinetic endpoints: serum SA237 concentrations
Immunogenicity endpoints: Incidence of anti-SA237 antibodies
Exploratory Endpoint: Additional pain assessment |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 40 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
France |
Germany |
Hungary |
Italy |
Japan |
Poland |
Spain |
Taiwan |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |